)
AstraZeneca Pharma India has soared 17% to Rs 1,002 on the NSE in an otherwise weak market after the company reported a standalone net profit of Rs 38.13 crore in the fourth quarter ended March 31, 2015 (Q4) against a loss of Rs 2.57 crore in the year-ago quarter.
Total income from operations during the quarter under review increased by 48% to Rs 169 crore against Rs 114 crore in the corresponding quarter of previous year.
The company earned Rs 48 crore as service income pertaining to clinical trials and co-promotion activities during the quarter, AstraZeneca Pharma India said in a statement.
The stock hit a high of Rs 1,016 and has seen a combined 469,036 shares changing hands on the counter on the NSE and BSE so far.
At 1448 hours, the stock was up 15% to Rs 983 on the NSE.
Total income from operations during the quarter under review increased by 48% to Rs 169 crore against Rs 114 crore in the corresponding quarter of previous year.
The company earned Rs 48 crore as service income pertaining to clinical trials and co-promotion activities during the quarter, AstraZeneca Pharma India said in a statement.
The stock hit a high of Rs 1,016 and has seen a combined 469,036 shares changing hands on the counter on the NSE and BSE so far.
At 1448 hours, the stock was up 15% to Rs 983 on the NSE.
